Equities research analysts forecast that Pluristem Therapeutics Inc. (NASDAQ:PSTI) will report earnings per share (EPS) of ($0.09) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Pluristem Therapeutics’ earnings. The lowest EPS estimate is ($0.09) and the highest is ($0.08). Pluristem Therapeutics also posted earnings per share of ($0.09) during the same quarter last year. The company is scheduled to announce its next earnings report on Monday, May 14th.
On average, analysts expect that Pluristem Therapeutics will report full-year earnings of ($0.34) per share for the current fiscal year, with EPS estimates ranging from ($0.34) to ($0.33). For the next financial year, analysts forecast that the company will report earnings of ($0.31) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Pluristem Therapeutics.
PSTI has been the topic of several analyst reports. Zacks Investment Research upgraded Pluristem Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research note on Saturday, March 24th. HC Wainwright set a $4.00 target price on Pluristem Therapeutics and gave the company a “buy” rating in a research note on Tuesday, January 16th. Finally, Maxim Group set a $3.00 target price on Pluristem Therapeutics and gave the company a “buy” rating in a research note on Wednesday, February 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $3.38.
In related news, Director Mark Germain sold 45,873 shares of Pluristem Therapeutics stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $1.48, for a total value of $67,892.04. Following the sale, the director now directly owns 525,584 shares in the company, valued at $777,864.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 7.20% of the stock is owned by insiders.
Several institutional investors have recently bought and sold shares of PSTI. ARK Investment Management LLC boosted its stake in shares of Pluristem Therapeutics by 363.5% in the fourth quarter. ARK Investment Management LLC now owns 290,922 shares of the biotechnology company’s stock valued at $401,000 after buying an additional 228,149 shares in the last quarter. Meitav Dash Investments Ltd. purchased a new stake in shares of Pluristem Therapeutics in the fourth quarter valued at approximately $138,000. Finally, Jane Street Group LLC boosted its stake in shares of Pluristem Therapeutics by 15.0% in the third quarter. Jane Street Group LLC now owns 266,043 shares of the biotechnology company’s stock valued at $402,000 after buying an additional 34,742 shares in the last quarter. Hedge funds and other institutional investors own 4.17% of the company’s stock.
Shares of PSTI stock opened at $1.24 on Tuesday. Pluristem Therapeutics has a twelve month low of $1.06 and a twelve month high of $2.12. The company has a market capitalization of $131.93, a price-to-earnings ratio of -3.88 and a beta of 0.28.
ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Expect Pluristem Therapeutics Inc. (PSTI) to Announce -$0.09 Earnings Per Share” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/20/zacks-analysts-expect-pluristem-therapeutics-inc-psti-to-announce-0-09-earnings-per-share.html.
About Pluristem Therapeutics
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.